These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30627273)

  • 21. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes.
    Ishii S; Nagai Y; Kato H; Fukuda H; Tanaka Y
    J Clin Med Res; 2020 Feb; 12(2):122-126. PubMed ID: 32095182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Hiroi S; Hirayama M; Kaku K
    J Diabetes Investig; 2012 Dec; 3(6):517-25. PubMed ID: 24843617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes.
    Takahara M; Shiraiwa T; Matsuoka TA; Yamamoto K; Maeno Y; Shiraiwa Y; Yoshida Y; Katakami N; Iijima H; Katsumata H; Arakawa K; Hashimoto T; Shimomura I
    Diabetes Metab Syndr Obes; 2020; 13():4457-4468. PubMed ID: 33244248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus.
    Kumar S; Pathak AK; Saikia D; Kumar A
    J Clin Diagn Res; 2015 Dec; 9(12):FC07-10. PubMed ID: 26816909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients.
    Hussain M; Rafique MA; Iqbal J; Akhtar L
    Pak J Med Sci; 2019; 35(2):383-387. PubMed ID: 31086519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine.
    Mathieu C; Shankar RR; Lorber D; Umpierrez G; Wu F; Xu L; Golm GT; Latham M; Kaufman KD; Engel SS
    Diabetes Ther; 2015 Jun; 6(2):127-42. PubMed ID: 25820927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
    Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea.
    Kim HS; Kim DM; Cha BS; Park TS; Kim KA; Kim DL; Chung CH; Park JH; Jang HC; Choi DS
    J Diabetes Investig; 2014 Nov; 5(6):701-8. PubMed ID: 25422771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
    Smulders RA; Zhang W; Veltkamp SA; van Dijk J; Krauwinkel WJ; Keirns J; Kadokura T
    Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of initial treatment with glimpeiride versus sitagliptin in type 2 diabetes].
    Tamez-Pérez HE;
    Rev Med Inst Mex Seguro Soc; 2015; 53(2):142-8. PubMed ID: 25760742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea.
    Kubota A; Yabe D; Kanamori A; Kuroe A; Takahashi N; Saito T; Matsuba I; Nabe K; Kurose T; Seino Y
    J Diabetes Investig; 2014 Jul; 5(4):445-8. PubMed ID: 25411605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
    Sato D; Sato Y; Masuda S; Kimura H
    Drug Saf; 2013 Aug; 36(8):605-15. PubMed ID: 23700263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study.
    Kojima Y; Kaga H; Hayashi S; Kitazawa T; Iimura Y; Ohno M; Yoshitsugu M; Fujiwara M; Hiyoshi T
    World J Diabetes; 2013 Feb; 4(1):8-13. PubMed ID: 23493856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study.
    Takeshita Y; Takamura T; Kita Y; Takazakura A; Kato K; Isobe Y; Kaneko S
    BMJ Open Diabetes Res Care; 2015; 3(1):e000122. PubMed ID: 26336611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.